Treats seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or…. Sold as Epidiolex. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Cannabidiol (sold as Epidiolex), first approved Jun 25, 2018, with 3 new uses approved and 0 published complete response letters.
| Efficacy of Vaped Cannabidiol in Cannabis Use DisorderCannabis Use Disorder · University Hospital, Bordeaux | Not applicable | Not yet recruiting | Nov 12, 2026 |
| A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Cannabidiol Capsules (AVAT-121) and Epidyolex® in Healthy AdultsFocal Onset Seizure · Avata Biosciences Holdings Ltd | Phase 1 | Not yet recruiting | Nov 5, 2026 |
| Effects of Cannabidiol on Memory and Attention in Adults Aged 60-70: A Pilot StudyHealthy Aging, Cognition · Medical University of Silesia | Not applicable | Not yet recruiting | Nov 2, 2026 |
| Cannabidiol in Opioid Use Disorder and Chronic Pain With BuprenorphineChronic Pain, Opioid Use Disorder · Yale University | Early phase 1 | Recruiting | Oct 21, 2026 |
| Effects of Cannabidiol (CBD) on a Fixed Dose of Delta-9-tetrahydrocannabinol (THC)Cannabis Intoxication · Johns Hopkins University | Phase 1 | Not yet recruiting | Oct 13, 2026 |
| Oral and Topical Phytocannabinoids for PsoriasisPsoriasis Vulgaris · Federal University of Latin American Integration | Phase 2 | Active, not recruiting | Sep 24, 2026 |
| CannaRiver CBD Calm for Anxiety, Sleep, and Well-Being in Adults With Generalized Anxiety DisorderGeneralized Anxiety Disorder · Associação Pan-Americana Multidisciplinar de Endocanabinologia | Not applicable | Not yet recruiting | Sep 16, 2026 |
| Full-Spectrum Cannabis Extract for Chronic Pain and Bone Health Biomarkers in WomenChronic Pain, Fibromyalgia · Associação Pan-Americana Multidisciplinar de Endocanabinologia | Phase 2 | Not yet recruiting | Aug 24, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jun 25, 2018 | EpidiolexNDA 210365 · New molecular entity | Jazz Pharms Res | 16 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
